Ono Pharmaceutical (OTCMKTS:OPHLF) Stock Crosses Above 50-Day Moving Average - Here's Why

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report)'s stock price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $10.60 and traded as high as $12.58. Ono Pharmaceutical shares last traded at $11.50, with a volume of 781 shares traded.

Ono Pharmaceutical Stock Performance

The company's 50 day moving average price is $10.69 and its two-hundred day moving average price is $10.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.07 and a quick ratio of 2.56. The stock has a market capitalization of $5.74 billion, a PE ratio of 19.71 and a beta of 0.51.

Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.34 by ($0.08). The business had revenue of $886.27 million during the quarter, compared to analysts' expectations of $827.29 million. Ono Pharmaceutical had a return on equity of 5.49% and a net margin of 8.75%.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.